Definitive Healthcare Corp. (NASDAQ:DH) Stock Has Consensus Price Target of $1.47 According to Brokerages

Posted by Brenda Bartman on Oct 17th, 2026

Shares of Definitive Healthcare Corp. (NASDAQ:DH – Get Free Report) have received a consensus rating of “Reduce” from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $1.47.

Several analysts have weighed in on DH shares. Bank of America reissued an “underperform” rating and issued a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th. Morgan Stanley decreased their price objective on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. BTIG Research reissued a “neutral” rating on shares of Definitive Healthcare in a research note on Friday, September 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Monday, August 31st.

View Our Latest Stock Report on Definitive Healthcare

Hedge Funds Weigh In On Definitive Healthcare

Large investors have recently bought and sold shares of the stock. Corient Private Wealth LP bought a new stake in Definitive Healthcare in the second quarter valued at approximately $378,000. Squarepoint Ops LLC grew its holdings in shares of Definitive Healthcare by 46.5% in the second quarter. Squarepoint Ops LLC now owns 351,575 shares of the company’s stock worth $292,000 after purchasing an additional 111,634 shares during the last quarter. Williams & Novak Wealth Management LLC increased its stake in shares of Definitive Healthcare by 15.3% in the third quarter. Williams & Novak Wealth Management LLC now owns 90,610 shares of the company’s stock worth $82,000 after buying an additional 12,000 shares during the period. Williams & Novak LLC increased its stake in shares of Definitive Healthcare by 155.8% in the second quarter. Williams & Novak LLC now owns 78,610 shares of the company’s stock worth $65,000 after buying an additional 47,880 shares during the period. Finally, Flywheel Private Wealth LLC purchased a new position in shares of Definitive Healthcare in the first quarter worth $83,000. 98.67% of the stock is owned by hedge funds and other institutional investors.

Definitive Healthcare Price Performance

NASDAQ DH traded up $0.00 on Friday, reaching $1.00. 187,834 shares of the company’s stock traded hands, compared to its average volume of 736,680. Definitive Healthcare has a 12 month low of $0.61 and a 12 month high of $3.04. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86. The stock has a 50-day simple moving average of $0.90 and a 200 day simple moving average of $0.88. The stock has a market cap of $106.75 million, a PE ratio of -0.62, a P/E/G ratio of 12.29 and a beta of 1.40.

Definitive Healthcare (NASDAQ:DH – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. Definitive Healthcare had a negative net margin of 72.28% and a positive return on equity of 3.55%. The firm had revenue of $55.20 million during the quarter, compared to analyst estimates of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. As a group, research analysts predict that Definitive Healthcare will post 0.06 earnings per share for the current year.

About Definitive Healthcare

(Get Free Report)

Definitive Healthcare Corp. is a healthcare commercial intelligence company that provides data, analytics and software to help organizations understand the healthcare market. Its platform is designed to support decision-making across areas such as sales and marketing, market access, provider network strategy, competitive intelligence and healthcare operations.

The company’s products combine information on healthcare providers, hospitals, health systems, medical groups, payers, procedures and related market activity.